Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Midazolam Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects

NCT00410254
View directory record Official record
Conditions
Healthy
Interventions
HCV-796, midazolam
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 19, 2026, 3:38 AM EDT
Active, not recruiting Phase 3 Interventional

Goal-Directed Sedation in Mechanically Ventilated Infants and Children

NCT04801589
View directory record Official record
Conditions
Delirium, Critical Illness, Sedation Complication, Executive Dysfunction, Post Traumatic Stress Disorder
Interventions
Dexmedetomidine, Midazolam
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
44 Weeks to 11 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Terminated No phase listed Observational

Olanzapine Versus Midazolam for Agitation

NCT03899506
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Olanzapine, Midazolam
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 19, 2026, 3:38 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 2 Interventional

Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.

NCT00248729
View directory record Official record
Conditions
Respiratory Failure
Interventions
Etomidate (20mg) or Midazolam (7mg)
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Sedation on Cognitive Performance in the Elderly

NCT03089866
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction
Interventions
Midazolam (0.02mg/kg)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

NCT06360211
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions
BAY2927088, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

NCT06106009
View directory record Official record
Conditions
Healthy
Interventions
PF-07976016, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

NCT04138836
View directory record Official record
Conditions
Healthy Participants
Interventions
BBT-877, Midazolam, Itraconazole, Esomeprazole
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Results available

A Study of Ixekizumab in Participants With Plaque Psoriasis

NCT02993471
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

NCT03723395
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D

NCT02635282
View directory record Official record
Conditions
Abscess, Pain
Interventions
intranasal ketamine, intranasal fentanyl, intranasal midazolam
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
3 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Results available

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

NCT01937260
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Anaheim, California • Irvine, California • Ocala, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Oral Sedation-related Events of Three Multiagent Oral Sedation Regimens in Pediatric Dental Patients

NCT05126459
View directory record Official record
Conditions
Anxiety, Dental, Dental Decay
Interventions
Regimen 1, Regimen #2, Regimen #3
Combination Product
Lead sponsor
Loma Linda University
Other
Eligibility
3 Years to 7 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Healthy Participants

NCT03929744
View directory record Official record
Conditions
Healthy
Interventions
LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

NCT01873339
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

NCT04592809
View directory record Official record
Conditions
Suicide, Attempted, Suicide and Depression, Suicide Threat
Interventions
Ketamine Hydrochloride, Midazolam Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Not applicable Interventional

Anesthetics in Rhytidoplasty - A Comparison Study

NCT02410460
View directory record Official record
Conditions
Rhytidoplasty
Interventions
clonidine, glycopyrrolate, propofol, ketamine, marcaine, scopolamine, midazolam, ondansetron, metoclopramide, lidocaine, famotidine, desflurane, sevoflurane
Drug · Device
Lead sponsor
Mercy Facial Plastic Surgery Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Oct 19, 2026, 3:38 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

NCT07867340
View directory record Official record
Conditions
C-Reactive Protein
Interventions
LY5625573, Midazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Alamitos, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 3:38 AM EDT